Business
LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary
BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company’s Liora Technologies Europe Ltd. subsidiary (“Liora”). A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at
About this update from Lixte Biotechnology Holdings, Inc.
[{"type":"image","alt":"Lixte Biotechnology Holdings, Inc.","displaySize":"","headline":null,"caption":"Lixte Biotechnology Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":275,"height":120,"url":"https://media.zenfs.com/en/globenewswire.com/9518732e3aaf23fc68ee2aaea1795fc6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FmV0Y7aYPvvleZjVNFp7LQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9518732e3aaf23fc68ee2aaea1795fc6","width":275,"height":120}},"lazy":false},{"type":"text","content":"BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company’s Liora Technologies Europe Ltd. subsidiary (“Liora”).","length":365,"tagName":"p"},{"type":"text","content":"A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE’s acquisition of Liora’s assets in November 2025 from Orbit Capital, Inc.","length":321,"tagName":"p"},{"type":"text","content":"Over his career, Braun played a key role in building an infusion network for the biologic drug Remicade, which was approved to treat several immune-mediated inflammatory diseases. He also created a physician network in Canada that was sold to Toronto-based AIM Health Group. Braun is multi-lingual and holds degrees in economics and business administration from Fordham University.","length":381,"tagName":"p"},{"type":"text","content":"“The appointment of Sidney Braun as CEO of Liora is in keeping with our plan to bring Liora’s LiGHT System technology to the forefront of modern cancer treatment and eventually enable LIXTE to pursue a recurring revenue model,” said Geordan Pursglove, CEO of LIXTE. “We welcome Sidney to the LIXTE family and are confident of the contributions he will make to our organization and to advancing and scaling an important technology in cancer treatment.”","length":451,"tagName":"p"},{"type":"text","content":"“Leadership in breakthrough medical technology is about building via...